IMR Press / EJGO / Volume 25 / Issue 2 / pii/2004131

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Editorial Article

Anti human papillomavirus vaccine: The checkmate to human papillomavirus?

Show Less
1 School of Medicine and Surgery 11, “La Sapienza” University Sant’Andrea Hospital, Rome (Italy)
Eur. J. Gynaecol. Oncol. 2004, 25(2), 151–156;
Published: 10 April 2004
Abstract

Cervical cancer is the second most frequently found neoplasia in women worldwide. At least 95% of cervical cancers contain viral DNA which, in 80% of cases, belongs to one of the human papillomavirus (HPV) viral types at high oncogenic risk: 16, 18, 31 and 45. HPV is, at this point, considered the first “necessary cause” of cervical cancer, against which primary prevention with a reduction in the risk of infection can be carried out. Numerous molecular biological studies have been con­ducted to identify the biological markers of this infection and to refine an effective and well tolerated vaccine capable of pre­venting HPV infection as well as possibly treating those cases in which the infection has already caused an HPV-related disease of the genital tract. In the near future, the real primary prevention of this disease will be conducted, similar to what occurred for Hepatitis B, using immunoprophylaxis with an anti-cancer vaccine.

Keywords
Human papillomavirus
Vaccine
Clinical trial
Share
Back to top